Latest News Allegro Ophthalmics Names CFO and Medical Director By Staff Friday, October 23, 2015 12:18 AM SAN JUAN CAPISTRANO, Calif.—Allegro Ophthalmics, LLC, a biotechnology company focused on the development of therapies to treat vitreoretinal diseases, announced that Scott Cooper has joined the company as chief financial officer (CFO) and VP of business development, and that Mohamed Genead, MD, has been named executive medical director.“We are delighted to welcome Scott and Mohamed to Allegro,” said Hampar Karageozian, MSc, MBA, co-founder and CEO, Allegro Ophthalmics. “Scott’s incredibly successful record at WaveTec and IntraLase demonstrates how exceptionally well-prepared he is to lead Allegro’s finance and business development functions. “Mohamed’s exceptional 15 years of clinical research and drug development experience in retina will serve Allegro well as we move our lead investigational drug Luminate through multiple clinical trials for several vitreoretinal indications. With these two new additions, Allegro is poised for much growth and success.” A veteran finance executive, Cooper has spent nearly his entire career, which spans more than 25 years, in financial operations and accounting at numerous medical device and high-tech companies, and has worked for ophthalmic medical device companies for the last 11 years. Most recently, he served as the CFO of WaveTec Vision Systems, Inc., joining the company in 2007. In his role at Allegro, Dr. Genead will work to drive the Luminate platforms into further clinical development as he works closely with the R&D, manufacturing, product development teams, and will be responsible for running the U.S. and international clinical studies of Luminate in diabetic macular edema (DME) and posterior vitreous detachment. Prior to joining Allegro, Dr. Genead was global medical director of clinical development in the ophthalmology/retina therapeutics area at Allergan.